Shield Therapeutics (AIM:STX) has agreed to take full commercial control of ACCRUFeR (ferric maltol) in the United States from Viatris, with closing expected on 30 September.
The London-listed, commercial-stage pharmaceutical company focuses on treating iron deficiency, and the US is its largest and fastest-growing market for the drug. Going forward, Shield will retain all gross profit from US sales, paying Viatris a royalty starting in the high single digits and rising to the mid-teens over a five-year term, with no upfront payment due.
The company will absorb the dedicated US sales force it has run jointly with Viatris since 2022, alongside direct control of pricing, market access and prescriber data.
Shield said the deal enhances its expectation of reaching operating profitability in 2026, driven by stronger net sales retention, improved margins and greater cash generation.
"By assuming full commercial control of our most important market, we significantly enhance the economics of the business, strengthen our ability to execute our growth strategy and create a scalable commercial platform for the future," said chief executive Anders Lundstrom.
He added that the increased cost base from absorbing the sales team is expected to be more than offset by improved margins.
News Intelligence what this means for the company
Shield Therapeutics is taking full commercial control of ACCRUFeR in the US from Viatris, absorbing the joint sales force and retaining all gross profit in exchange for a royalty starting in the high single digits and rising to mid-teens. The company expects this to accelerate its path to operating profitability in 2026 by improving margins and cash generation, despite the added cost of running the sales force independently.
This deal removes a structural drag on Shield's US economics—the largest and fastest-growing market for ACCRUFeR—by converting a profit-share arrangement into a royalty structure that lets the company capture upside from pricing and market access decisions. The timing aligns with pediatric indication extensions approved in the US, Europe, and the UK on 20 August 2026, which could expand the addressable patient population and support the 2026 profitability target.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
